Proteasome inhibitors (PIs) are promising new therapeutic agents for treating non-small cell lung carcinoma (NSCLC). To investigate the mechanisms of action of PIs, we analyzed the proapoptotic activities of PIs (MG132 or Bortezomib) in NSCLC cells. We found that both MG132 (>1 lM) and Bortezomib (>0.025 lM) induced a significant apoptosis in NCI-H1703, a PI-sensitive NSCLC cell line, through initially activating the intrinsic apoptosis pathway, leading to the activation of a positive feedback mechanism (PFM), which then conveyed apoptosis signaling from the intrinsic pathway to the extrinsic pathway with formation of a signaling loop for maximal caspase activation. Mcl-1 and Noxa were identified to be the major anti-apoptotic and proapoptotic proteins, respectively, in PI-induced apoptosis and mutually exclusive in protein stability. Although the Mcl-1 protein was upregulated by proteasome inhibition, it was also subjected to caspase 3-dependent cleavage governed by the PFM. Moreover, it was revealed that Mcl-1 protein cleavage contributed to PFM-governed apoptosis in following inter-related ways: reducing the anti-apoptotic Mcl-1; generating the truncated proapoptotic Mcl-1 S ; and inducing a shift of balance between Mcl-1 and Noxa. It was further manifested that tumor necrosis factorrelated apoptosis-inducing ligand boosted MG132's proapoptotic activity through strengthening the PFM in both NCI-H1703 and NCI-H358, a PI-resistant NSCLC cell line. Therefore, this study provides a basis for enhancing the efficacy of PIs in treating NSCLC.
Introduction
Lung cancer, of which approximately 85% are nonsmall cell lung carcinoma (NSCLC), is the leading cause of cancer death in both men and women in the United States (Jemal et al., 2005) . Although closely related to tobacco use, lung cancer is also ranked second only to bladder cancer in the proportion of cases thought to be associated with occupational exposures (Steenland, 1996) . Owing to the low sensitivity to current chemotherapies, and the limited number of cancer patients for new targeting therapies, such as anti-EGFR (epidermal growth factor receptor) and anti-VEGFR (vascular endothelial growth factor receptor) therapies, lung cancer still carries a poor prognosis with a five year survival rate of 15% (Molina et al., 2008) .
Proteasome inhibitors (PIs) have become promising agents for treating lung cancers. The proteasome is a large catalytic complex responsible for degrading most non-lysosome targeting proteins in a controlled manner. This structure is a promising target for cancer therapy because it can impact cell cycle, apoptosis, proliferation and other cellular processes by regulating the important signaling proteins, such as CDC25A (cell division cycle 25A), MDM2 (murine double minute 2), p27/KIP1 and I-kB (Adams, 2004) . Bortezomib is the first PI approved by the Food and Drug Administration (FDA) for treating the relapsed multiple myeloma and has produced encouraging anti-tumor activity alone or in combination with other cytotoxic drugs in NSCLC patients (Davies et al., 2007) .
In various types of human cancer, PIs reduce the viability of tumor cells by inducing apoptosis (Henderson et al., 2005) . Caspases, both the initiator caspases, such as caspases 8, 9 and 10, and the executioner caspases, like caspases 3 and 7 (Cryns and Yuan, 1998) , are involved in PI-induced apoptosis (Yuan et al., 2008) . The intrinsic (or mitochondrial) apoptosis pathway, regulated mainly by the Bcl-2 family member proteins (Strasser, 2005) , represents a fundamental mechanism for the apoptosis triggered by proteasome inhibition (Voortman et al., 2007) .
The Bcl-2 family members belong to three different classes of proteins based on their Bcl-2 homology (BH) domains, which include multidomain anti-apoptotic (Bcl-2, Bcl-X L and Mcl-1), multidomain proapoptotic (Bak and Bax) and BH3-only proapoptotic proteins. BH3-only proteins can be further divided into activator (Bid and Bim) and sensitizer/derepressor (Noxa, Bik, Bad, Bmf and Hrk) members (Certo et al., 2006) . Activator-type BH3-only proteins directly induce oligomerization/activation of Bax and Bak, causing mitochondrial outer membrane permeabilization and subsequent release of cytochrome c (cyto c) and Smac/ DIABLO (Smac) to activate downstream caspases and neutralizing inhibitors of apoptosis proteins (IAPs), respectively (Green, 2006) . However, sensitizer/ derepressor-type BH3-only proteins interact with antiapoptotic members, indirectly activating Bak and Bax (Letai et al., 2002) . Thus, the balanced expression between proapoptotic and anti-apoptotic Bcl-2 proteins is critical in determining whether a cell will undergo apoptosis.
Despite the promising proapoptotic activity, we have found that various cancer cells, including NSCLC cells, are resistant or less sensitive to PI-induced apoptosis. All these cells show a significant elevation in Mcl-1 protein level following PI treatment (Yuan et al., 2008) . The Mcl-1 protein inhibits apoptosis by sequestering the Bak protein from activating mitochondrial outer membrane permeabilization (Willis et al., 2005) . It is subjected to both proteasome-mediated protein degradation (Cuconati et al., 2003) and caspase 3-dependent protein cleavage (Weng et al., 2005) . Therefore, it is important to comprehend the function of Mcl-1 in regulating PI-induced apoptosis for better understanding the mechanism for resistance to PI treatment.
In this study, we observed a dual change in Mcl-1 protein level in NSCLC cells induced by PIs which led to the discovery of a positive feedback mechanism (PFM), an efficient apoptosis-inducting mechanism. Using a comprehensive analysis of the PFM and its relationship with Mcl-1, we proposed that Mcl-1 protein cleavage might serve as a biomarker for evaluating the efficacy of PI treatment and for designing new PI-based combination therapies for treating NSCLC.
Results

MG132 induces apoptosis in NSCLC cells
NSCLC cell lines NL20TA, NCI-H23, NCI-H358, NCI-H522, and NCI-H1703 were randomly chosen for treatment with 0.5-4 mM MG132 (Yuan et al., 2008) to study the function of PIs in the treatment of NSCLCs. Among them, NL20TA and NCI-H1703 showed the highest cell death to as low as 0.5 mM MG132 at 24 h, whereas NCI-H522 and NCI-H23 showed a moderate cell death, and NCI-H358 presented the lowest cell death (Figure 1a) . We then focused NCI-1703 cells in analyzing MG132-induced cell death and the underlying mechanisms. It was found that MG132 induced shrinkage and membrane blebbings (Figure 1b) , and DNA damage, as revealed by the sub-G1/G0 fraction in a flow cytometry assay, with a significant G2/M phase arrest ( Figure 1c ) in NCI-H1703 cells, suggesting MG132 induced an apoptotic cell death.
MG132 induces a caspase-dependent apoptosis
We next examined protein cleavages of caspases 3, 7, 8, 9 and 10, Bid and poly (ADP-ribose) polymerase (PARP), the hallmark events of caspase-dependent apoptosis, in MG132-treated NCI-H1703 cells. Western blotting revealed a dose-dependent cleavage of all proteins, except caspase 8 (Figure 2A ). To determine the caspase-dependent nature, we co-treated cells with 0.5 mM MG132 and 10 mM specific inhibitor for caspase 3 (Z-DQMD) or caspase 9 (Z-LEHD). Z-VAD and Z-FA were used as positive and negative controls, respectively. It was found that both Z-DQMD and Z-LEHD significantly inhibited MG132-induced cell death, sub-G0/G1 fraction, and cleavages for PARP and caspase 3 (Figures 2Ba-c) , suggesting that MG132 induces a caspase-dependent apoptosis in which both the intrinsic and extrinsic pathways are involved. However, caspase inhibitors showed no effect on G2/M arrest.
The intrinsic apoptosis pathway is initially activated by MG132 To determine which apoptosis pathway was initially activated by MG132, we overexpressed Bcl-X L or dominant-negative Fas-associated protein with death domain (FADDdn) protein in NCI-H1703 cells before MG132 treatment. Bcl-X L primarily regulates the intrinsic pathway (Green, 2006) , whereas FADDdn blocks the extrinsic pathway (Muzio et al., 1996) . It was found that the overexpressed Bcl-X L , but not FADDdn, significantly reduced MG132-induced protein cleavages (Figure 3a) , although the overexpressed FADDdn clearly inhibited tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced protein cleavages ( Supplementary Figure 1) , suggesting that the intrinsic pathway, rather than the extrinsic pathway, is initially activated by MG132.
In agreement with activation of the intrinsic pathway, we also observed a significant mitochondrial release of both Smac and cyto c with more significance seen in Smac (Figure 3b ). However, neither cytosolic apoptosis inducing factor (AIF) (data not shown) nor AIF protein nuclear translocation was observed even in the cells undergoing a clear apoptosis (Supplementary Figure 2) . Given AIF nuclear translocation from the mitochondria is associated with caspase-independent apoptosis (Cregan et al., 2004) , we conclude that MG132-induced apoptosis is a consequence of mitochondrial caspase activation.
Mcl-1 protein cleavage contributes to MG132-induced apoptosis
To analyze the MG132-activated intrinsic pathway, we then examined protein expression of Bcl-2, Bcl-X L and Mcl-1 in MG132-treated cells. It was found through western blotting that MG132 treatment showed no effect on both Bcl-2 and Bcl-X L (Figure 4Aa ), but, interestingly, induced a dual change in Mcl-1 protein level: reduction by high dose MG132 (greater than 1 mM) and elevation by low dose MG132 (lower than 1 mM). As the Mcl-1 protein is subjected to both caspase 3-dependent protein cleavage and proteasome-mediated protein degradation, the Mcl-1 protein levels to different doses of MG132 may reflect the dominance of either caspase activation or proteasome inhibition.
To examine proteasome inhibition on Mcl-1 protein elevation, we tested Mcl-1 protein ubiquitination. A large amount of poly-ubiquitinated Mcl-1 was detected in MG132-treated cells, suggesting that proteasome inhibition contributes to Mcl-1 protein accumulation ( Figure 4Ab ). Next, to determine the contribution of caspase 3 to Mcl-1 protein cleavage, we co-treated tumor cells with 10 mM caspase 3 inhibitor and 1 mM MG132, and found that caspase 3 inhibitor completely blocked the reduction of Mcl-1 protein level, but showed no effect on Bcl-2 protein level (Figure 4Ac ), supporting that caspase 3 activation causes Mcl-1 protein cleavage and such effect becomes dominant over proteasome inhibition in high dose MG132-treated cells.
To determine the role of Mcl-1 in regulating MG132-induced apoptosis, low dose MG132 in particular, we silenced Mcl-1 protein expression using its siRNA in NCI-H1703 cells before treating them with 0.125-0.25 mM MG132. As compared with control and Bcl-2 siRNAs, Mcl-1 siRNA markedly sensitized tumor cells to MG132-induced cell death (data not shown) and protein cleavages ( Figure 4B ), supporting that Mcl-1 is a major inhibitory protein in MG132-induced apoptosis.
As the C-terminal Mcl-1 cleavage fragment (Mcl-1 S ) may act as a proapoptotic protein (Weng et al., 2005) , we then tested the effect of Mcl-1 S on MG132-induced apoptosis. It was found that the expression of the Mcl-1 S protein alone did not induce a visible cytotoxicity (data not shown), but clearly sensitized NCI-H1703 cells to MG132-induced apoptosis ( Figure 4C ), suggesting that Mcl-1 protein cleavage contributes to MG132-induced apoptosis through reducing the anti-apoptotic Mcl-1 protein as well as converting it into the proapoptotic Mcl-1 S protein. not shown) and protein cleavages (Figure 5b ). In addition, we found that Mcl-1 antibody also precipitated Noxa protein, including the ubiquitinated form, from MG132-treated cells (Figure 4Ab ), supporting that Noxa is responsive to proteasome inhibition and acts as a major proapoptotic protein in PI-induced apoptosis by interacting with Mcl-1 (Willis et al., 2005) . Most interestingly, we observed that Noxa silencing induced a significant elevation of Mcl-1 protein level, whereas Mcl-1 silencing induced a significant elevation of Noxa protein level (Figure 5b ), therefore, revealing a mutually exclusive relationship between these two binding partners. Through Mcl-1 cleavage, a proapoptotic shift of the balance between Mcl-1 and Noxa was then induced and contributed to MG132-induced apoptosis.
Caspase 10 is activated by caspase 3 through the PFM We observed that, in addition to the significantly enhanced cleavage of caspase 3 and PARP, Mcl-1 siRNA also assisted low dose MG132 inducing cleavage of both caspase 10 and Bid ( Figures 4B and 5b) . Given the fact that Mcl-1 inhibits apoptosis through primarily regulating the intrinsic rather than the extrinsic pathway and the afore-mentioned finding that MG132 induces apoptosis through initiating the intrinsic pathway, we speculated that caspase 10 cleavage was achieved through a feedback mechanism, which depended on caspase 3/7 activation. Supportive to this hypothesis, we found that caspase 3 inhibition by its specific inhibitor also blocked the cleavage of both caspase 10 and Bid (Figure 6a) .
Meanwhile, we observed that inhibition of either caspase 8 or 10 by each specific inhibitor significantly reduced cleavage of Bid, PARP and caspase 7, showing that caspase 8/10, together with caspases 3/7 and 9, contributed to MG132-induced apoptosis, although caspase 8 activation was not dependent on protein cleavage (Figure 6b) .
To further support the feedback mechanism and its effect on caspase 10 activation, we examined the kinetics of the major molecular events so far described. Following a time course observation, we found that, after treatment with 1 mM MG132, mitochondrial release of the Smac protein appeared at 7 h and protein cleavage of PARP, caspases 9, 3 and 7, and DNA damage, as indicated by pH2AX, began at 9 h and became much intensified thereafter (Figure 6c ), supporting the idea that mitochondrial release of Smac leading to an initial activation of caspases 9, 3/7 was an early event in MG132-induced apoptosis. However, the significant cyto c release, and cleavage of both caspase 10 and Mcl-1 emerged around 15 h (Figure 6c ), a timing of the enhanced activation of caspases of the intrinsic pathway, supporting that cleavage of caspase 10 and Mcl-1, which underwent a marked elevation at earlier time points, were downstream events of the initially activated caspase 3/7. In comparison to Smac, cyto c release was more likely the consequence of the secondarily activated caspase 8/10 and Bid (Nagy et al., 2006) . Taken together, these findings supported the existence of a feedback mechanism, which conveys apoptosis signaling from the intrinsic pathway through caspase 3/7 to the extrinsic pathway causing caspase 8/10 activation. Consequently, an apoptosis-signaling loop between two apoptosis pathways was then formed through the activated Bid protein. Further ensured by the resultant Mcl-1 protein cleavage, the apoptosis-signaling loop effects quickly amplified caspase activation. Owing to its amplification outcome, such a feedback mechanism can, therefore, be defined as the PFM.
TRAIL compensates insufficiency of low dose MG132 in initiating the PFM Following PFM model, we believed that Mcl-1 inhibited low dose MG132-induced apoptosis by blocking the initiation of PFM and the subsequent activation of caspase 10 and Bid. Logically, other apoptosis stimuli which can activate caspase 3 may help generate sufficient feedback signaling for low-dose MG132 to the same level as induced by high-dose MG132 alone. To achieve it, we co-treated NCI-H1703 cells with 5 ng/ ml TRAIL and 0.4 mM MG132. TRAIL is a member of the tumor necrosis factor-a family proteins, which induce apoptosis through binding the death receptors and activating caspase 8/10 (Wang and El-Deiry, 2003) . It was found that, although TRAIL or MG132 alone were much less effective, combination of two agents resulted in a synergistic cell death (data not shown) and 
PFM-governed apoptosis may represent a general function of PIs
In this study, we also treated NCI-H1703 cells with Bortezomid in comparison with MG132. Both MG132 and Bortezomid are peptide-type PIs, although Bortezomib is more specific in inhibiting the chymotrypsin-like activity of the 26S proteasome (Adams, 2004) . It was found that as low as 0.025 mM Bortezomid induced a visible apoptosis, suggesting a much stronger proapoptotic effect of Bortezomid than MG132. However, both PIs showed an almost identical profile in Noxa elevation and protein cleavages, caspase 10 and Mcl-1 cleavages in particular; high-dose Bortezomib induced an almost complete cleavage of both caspase 10 and Mcl-1 (>0.1 mM for Mcl-1 and >0.05 mM for caspase 10), which was completely blocked by caspase 3 inhibitor (Figure 8) , supporting that the PFM-governed apoptosis represents a common consequence of proteasome inhibition.
Discussion
This study demonstrates that a PFM governs PI-induced apoptosis in NSCLC cells
The PFM establishes a feedback (or backward) cross talk to convey the apoptosis signaling from the PI-initiated intrinsic pathway to the extrinsic pathway.
Combining the well-characterized forward cross talk, which transmits the signaling from the extrinsic to the intrinsic pathway through the mitochondria, the PFM subsequently directs the formation of a signaling loop for quickly achieving maximal caspase activation. To ensure this process, the PFM also manages to downregulate Mcl-1 anti-apoptotic protein. Therefore, PFM represents a very efficient apoptosis induction mechanism of a multi-dimensional nature.
The PFM directs the activation of the extrinsic pathway through the initially activated intrinsic pathway Our data show that PIs activate both the intrinsic pathway, as indicated by mitochondrial release of Smac and cyto c and cleavage of caspase 9, and the extrinsic pathway, as reflected by caspase 10 and Bid cleavages. As PI-induced apoptosis can be inhibited by specific inhibitor of caspase 3, 9, 8 or 10, we conclude that both apoptosis pathways are involved in this process. We believe that the intrinsic pathway is initially activated by PIs from an observation that MG132-induced apoptosis is inhibited by the overexpressed Bcl-X L protein, but not by FADDdn protein. Bcl-X L primarily regulates the intrinsic pathway, whereas FADDdn inhibits the extrinsic pathway associated with death ligand-induced apoptosis (Muzio et al., 1996) .
We also believe that activation of the extrinsic pathway is directed by the PFM, which is a consequence of the initially activated intrinsic pathway. This belief is based on two separate avenues of evidence. The first one comes from the findings that the specific inhibitor for caspase 3 or caspase 9 inhibits caspase 10 cleavage. The second one derives from an observation with regard to the kinetics of major biochemical events relevant to PIinduced apoptosis revealing that the events associated with the intrinsic pathway occur earlier than that associated with the extrinsic pathway. In contrast to a well-characterized forward mechanism, which mediates a cross talk from the extrinsic pathway to the intrinsic pathway through the Bid protein, we propose a PFM which mediates a cross talk between two apoptosis pathways in a backward manner. Most importantly, through connecting two cross talks by the activated caspase 10 and Bid (Milhas et al., 2005) , the PFM subsequently directs the formation of an apoptosissignaling loop, along which the signaling continues to be amplified until the maximal caspase activation is achieved.
Mcl-1 regulates PI-induced apoptosis through blocking the apoptosis-signaling loop Among the anti-apoptotic Bcl-2 family proteins, Mcl-1 is likely the most important protein for regulating PIinduced apoptosis. PI treatment does not affect the expression of Bcl-2 and Bcl-X L , but significantly elevates Mcl-1 protein level through proteasome inhibition. Most importantly, Mcl-1 silencing, but not Bcl-2 silencing, markedly enhances MG132-induced apoptosis, supporting that Mcl-1 is the major anti-apoptotic protein against PI-induced apoptosis. In addition to proteasome-mediated protein degradation, Mcl-1 is also subjected to capase 3-dependent protein cleavage, as seen in high-dose PI-treated NCI-H1703 cells when caspase 3 is robustly activated. Clearly, Bcl-2 cleavage did not happen in our experiments although it was described in other NSCLC cells (Voortman et al., 2007 ). Mcl-1 protein level at a given time point is thus determined by a balance between proteasome inhibition and caspase activation; reduction in Mcl-1 protein level indicates the dominance of caspase activation over proteasome inhibition in highdose PI-treated cells. However, different from the proteasome-mediated Mcl-1 protein degradation, the caspase 3-dependent Mcl-1 protein cleavage produces a C-terminal proapoptotic Mcl-1 S fragment, which sensitizes NCI-H1703 cells to MG132-induced apoptosis, suggesting that Mcl-1 cleavage contributes to PIinduced apoptosis by converting Mcl-1 from an antiapoptotic protein to a proapoptotic Mcl-1 S protein. As either Mcl-1 siRNA or Mcl-1 S can help induce cleavage of both caspase 10 and Bid, the events needed for forming the apoptosis-signaling loop, we conclude that Mcl-1 acts as the major regulatory protein in PI-induced apoptosis by blocking the PFM-directed apoptosissignaling loop.
The PFM induces a proapoptotic shift of balance between Mcl-1 and Noxa Although Mcl-1 acts as a major anti-apoptotic protein, Noxa functions as a key proapoptotic protein in PIinduced apoptosis. In addition to Mcl-1, PIs also induce Noxa protein accumulation, probably through proteasome inhibition. In contrast to Mcl-1 silencing, Noxa silencing significantly inhibits MG132-induced apoptosis, showing that Noxa elevation promotes PI-induced apoptosis. Protein binding between Mcl-1 and Noxa in our study supports that Noxa enhances apoptosis through preferentially interacting with Mcl-1 to release the sequestered Bak from Mcl-1 binding (Willis et al., 2005) .
Most interestingly, Mcl-1 and Noxa seem to be mutually exclusive in protein stability. This finding, to our knowledge, reveals a new relationship between Mcl-1 and Noxa, although the reduction of Mcl-1 by overexpressed Noxa has been observed (Hassan et al., 2008) . A similar relationship also exists between Smac and X-linked IAP, which are binding partners involved in regulating several caspases (3, 7 and 9). Interaction of Smac and X-linked IAP triggers mutually exclusive, proteasome-mediated degradation of each binding partner (MacFarlane et al., 2002; Zhang et al., 2004) . It is, therefore, very likely that the binding-triggered protein degradation is also the basis of the mutual exclusion between Noxa and Mcl-1. Given the existence of this nature, it is inferred that the PFM can induce a proapoptotic shift of a dynamic balance between Mcl-1 and Noxa through caspase 3-dependent Mcl-1 protein reduction and Noxa elevation. This finding, therefore, adds another level of contribution of Mcl-1 protein cleavage to PI-induced apoptosis.
TRAIL compensates insufficiency for low-dose MG132 in activating the PFM As discussed above, low-dose MG132 induces only a limited apoptosis because of its insufficiency in activating PFM as evidenced from its failure to cleave both caspase 10 and Mcl-1 in NCI-H1703 cells. Clearly, as revealed in this study, the TRAIL protein can help activate the PFM. TRAIL recruits/activates caspase 8/10 through death receptor, DR4 or DR5, with subsequent activation of downstream caspases 3/7. TRAIL alone or in combination with other DNA damage agents is currently under intense trials to overcome resistance of cancer cells to chemotherapies (Saulle et al., 2007; Kruyt, 2008) . It is shown that, although TRAIL alone causes only a slight cleavage of both Mcl-1 and caspase 10, co-treatment with TRAIL and low-dose MG132 induces an almost complete cleavage of both proteins in a manner similar to that induced by high-dose MG132 alone treatment, indicating that the enhanced apoptosis results from the activation of the PFM. In agreement to this idea, a similar finding was also observed in NCI-358 lung cancer cells, which are not sensitive to MG132, but moderately sensitive to TRAIL. TRAIL and MG132 combination treatment also induced a synergistically increased apoptosis in NCI-H358 cells with a significant cleavage of both Mcl-1 and caspase 10, although such effect is less efficient than that observed in NCI-H1703 cells. These observations further support our hypothesis regarding the PFM and advance our understanding of the efficacy of TRAIL and PI combination therapy in cancer treatment.
The PFM-governed apoptosis may represent a fundamental mechanism for proteasome inhibition-induced apoptosis Both Bortezomib and MG132 are peptide-type PIs, although Bortezomib shows a much higher specificity in inhibiting proteasome (Adams, 2004) . Both PIs present the same apoptosis profile in NCI-H1703 cells with an identical cleavage of caspases of both the intrinsic and extrinsic pathways, and a similar blockage of caspase 10 and Mcl-1 cleavages through caspase 3 inhibitor. Moreover, both PIs can elevate Noxa protein to a maximal level when the Mcl-1 protein is completely cleaved, indicating that a proapoptotic shift of the balance between Mcl-1 and Noxa contributes to both PI-induced apoptosis. It is therefore suggested that the PFMgoverned apoptosis may serve as a fundamental mechanism for proteasome inhibition-induced apoptosis. In summary, this study presents a new apoptosis induction model, a positive feedback model regarding PI-induced apoptosis (Figure 9 ). According to this model, the intrinsic and extrinsic pathways are joined to form a signaling loop leading to quick amplification of caspase activation. The Mcl-1 protein cleavage serves as a very critical event to ensure the functioning of this signaling loop through interrelated ways: (1) such as IAPs and FADD-like IL-1b-converting enzyme inhibitory protein (Liu et al., 2006; Hunter et al., 2007) , may also be involved in this process. Among IAPs proteins we tested, X-linked IAP is reduced, whereas Survivin is induced, by MG132 in NCI-H1703 cells (Supplementary Figure 4) . In addition to proteasome inhibition plus caspase cleavage mechanism, other important mechanisms associated with nuclear factor kB and signal transducer and activator of transcription-3 protein (Jing and Tweardy, 2005) , may also be involved in regulating PFM-governed apoptosis by regulating the expression of the critical anti-apoptotic proteins. It is expected that further understanding of the PFM will provide more inputs for designing new effective PI-based combination treatments.
Materials and methods
Materials
(1) Cell lines: Human NSCLC cell lines NL20TA, NCI-H1703, NCI-H358, NCI-H522 and NCI-H23 were obtained from American Type Culture Collection and cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum. (2) Chemicals: MG132, a proteasome inhibitor; caspase inhibitors: for wide spectrum caspases (Z-VAD-fmk); caspase 3 (Z-DQMD-fmk); caspase 8 (Z-IETD-fmk); caspase 9 (Z-LEHD-fmk); and caspase 10 (Z-AEVD-fmk), and Z-FAfmk, a negative control for all caspases, were obtained from EMD-CalBiochem (San Diego, CA, USA); Bortezomib, a proteasome inhibitor, was obtained from ChemieTek (Indianapolis, IN, USA). The TRAIL protein was obtained from R&D Systems (Minneapolis, MN, USA). (3) siRNAs: siRNAs for silencing Bcl-2, Mcl-1 or Noxa and negative control siRNA were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). (4) Antibodies: antibodies against caspases 3, 7, 9 and 10, PARP, Smac, cyto c, AIF and phospho-histone H2AX, phosphorylated at serine 139 residue, (pH2AX) were purchased from Cell Signaling (Danvers, MA, USA); antibodies against caspase 8, Mcl-1 and Bcl-X L were obtained from Santa Cruz Biotechnology; antibodies against ubiquitin, Bcl-2 and actin purchased were from Sigma (Milwaukee, WI, USA).
Protein analyses
(1) Western blotting: procedures for conventional western blotting were followed for detecting expression and/or cleavage of apoptosis-related proteins in PI-treated cells.
(2) Mcl-1 protein ubiquitination: cell lysate extracted by RIPA lysis buffer was immunoprecipitated by Mcl-1 antibody using protein A/G agarose and then analyzed by western blotting using an anti-ubiquitin antibody. (3) Mitochondrial release of the proapoptotic proteins: a previously described procedure was followed to isolate and analyze the cytosol cyto c, Smac and AIF portions (Fiskum et al., 1980) . (4) AIF protein nuclear translocation: a previously described procedure for fluorescent immunohistochemical staining was followed to stain the AIF protein in MG132-treated cells (Yuan et al., 2007) .
Apoptosis determination
(1) Cell morphological changes: changes in the cell morphology including shrinkage, membrane blebbing were observed under the light microscope, and nuclear condensation or fragmentation were observed by fluorescent microscopy (Hacker, 2000) , (2) cell viability test was carried out using WST-1 (watersoluble tetrazolium salt 1) reagent (Roche, Indianapolis, IN, USA) (Yuan et al., 2008) , (3) sub-G0/G1 fraction reflecting DNA fragmentation was observed by a previously described procedure (Das et al., 1999) , and (4) western blotting for detecting pH2AX, a DNA damage marker (Rogakou et al., 1998) , and for caspase cleavages, were used in combination to determine apoptosis.
Constructs and gene transfection
Expression construct for human FADDdn was kindly provided by Dr Marta Muzio (Muzio et al., 1996) . A Mcl-1 cDNA encoding the truncated Mcl-1 S from residue 146, immediately after the TSTD caspase 3 cleavage site (Weng et al., 2005) , to the C-terminal end, was amplified by RT-PCR from NCI-H1703 cells with a FLAG tag at its 5 0 end and cloned in pcDNA3.1Zeo( þ ) vector under a cytomegalovirus promoter. Procedures for stable gene transfection described previously were followed (Yuan et al., 2007) . Cells resistant against Zeocin (50 ng/ml) were tested for PI-induced apoptosis. Cells transfected with vector alone were used as controls.
siRNA transfection Procedures for siRNA transfection described previously were followed to transfect Mcl-1, Noxa, Bcl-2 or the control siRNA into NCI-H1703 cells (Yuan et al., 2008) and silencing of the target gene was determined by western blotting. Each siRNA silencing experiment was repeated at least twice.
Statistics
Data for cell viability were expressed as the means±s.d. of at least two separate experiments. Comparison between group means was assessed using one-way analysis of variance with Newman-Keuls posttest (GraphPad Prism 3.0 Software, Inc., San Diego, CA, USA). Po0.05 was considered significant. 
